Browse > Article
http://dx.doi.org/10.4332/KJHPA.2020.30.3.311

A Critical Evaluation and International Comparison of Pharmaceutical Consumption and Sales Statistics  

Kim, Jihye (Department of Research, Health Insurance Review & Assessment Service)
Lee, Dahee (Department of Research, Health Insurance Review & Assessment Service)
Kim, Sooyon (Department of Research, Health Insurance Review & Assessment Service)
Kim, Dong-Sook (Department of Research, Health Insurance Review & Assessment Service)
Publication Information
Health Policy and Management / v.30, no.3, 2020 , pp. 311-325 More about this Journal
Abstract
Background: Health statistics of pharmaceutical use and expenditure are essential to make and implement evidence-based pharmaceutical policy. This study aims to demonstrate the methods and results of pharmaceutical consumption and sales in 2018 according to the sources and methods given by the Organization for Economic Cooperation and Development (OECD). Methods: The medication list contains 39,346 medicines both reimbursed and non-reimbursed by the National Health Insurance in 2018. We used the therapeutic categories based on Anatomic Therapeutic Chemical Classification of World Health Organization. This study analyzed National Health Insurance claims data and supply data generated from wholesalers to health care facilities. The indicators are defined daily dose (DDD), per 1,000 inhabitants per day and US$ per capita. Results: In South Korea, the number of medications to which DDD were assigned was 18,055 and it was 45.9% of the total number of medications on the list. The consumption in anti-infective for systemic use (J) and musculo-skeletal system (M) was higher than the mean consumption among the OECD countries. The pharmaceutical sales per person in Korea was also higher than the mean sales per person across the OECD countries. Conclusion: We sought to explain the methods to produce pharmaceutical consumption and sales statistics which we had submitted annually to OECD. Considering the characteristics of pharmaceutical statistics, a direct comparison should be approached with caution. Since the growth in pharmaceutical spending has greatly increased over the past decade, we need to monitor pharmaceutical consumption and expenditure consistently.
Keywords
Drug utilization review; Statistics; Pharmaceutical expenditure;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Vogler S, Zimmermann N. The potential of generics policies: more room for exploitation: PPRI conference report. Generics Biosimilars Initiat J 2012;1(3-4):146-149. DOI: https://doi.org/10.5639/gabij.2012.0103-4.030.   DOI
2 European Generic Medicines Association. How to increase patient access to generic medicines in European healthcare systems. Brussels: European Generic Medicines Association; 2009.
3 Organization for Economic Cooperation and Development. OECD homepage [Internet]. Paris: Organization for Economic Cooperation and Development [cited 2019 Dec 20]. Available from: https://www.oecd.org/.
4 Organization for Economic Cooperation and Development. OECD health data: pharmaceutical spending [Internet]. Paris: Organization for Economic Cooperation and Development; 2019 [cited 2019 Dec 20]. Available from: https://data.oecd.org/healthres/pharmaceutical-spending.
5 World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: Collaborating Centre for Drug Statistics Methodology; 2019.
6 Choi JS, Chae SE, Park GC, Cho YH, Cho SB. Health care utilization in 2018. Wonju: Health Insurance Review and Assessment Service; 2019.
7 Organization for Economic Cooperation and Development. Health at a glance 2019: OECD indicators. Paris: Organization for Economic Cooperation and Development; 2019.
8 Jung HS. Korean pharmaceutical expenditure according to OECD's system of health accounts. Korea J Health Policy Adm 2013;13(3):48-65. DOI: https://doi.org/10.4332/kjhpa.2003.13.4.48.
9 Jeong HS, Shin JW. 2015 National Health Accounts and current health expenditures in Korea. Health Policy Manag 2017;27(3):199-210. DOI: https://doi.org/10.4332/KJHPA.2017.27.3.199.   DOI
10 Jeong HS, Shin JW, Moon SW, Choi JS, Kim H. 2018 Current health expenditures and National Health Accounts in Korea. Health Policy Manag 2019;29(2):206-219. DOI: https://doi.org/10.4332/KJHPA.2019.29.2.206.   DOI
11 Health Insurance Review and Assessment Service. Statistics of reimbursement medication claims. Wonju: Health Insurance Review and Assessment Service; 2018.
12 Health Insurance Review and Assessment Service. Statistics of pharmaceutical supply. Wonju: Health Insurance Review and Assessment Service; 2018.
13 Health Insurance Review and Assessment Service. Report of pharmaceutical prescribing evaluation result. Wonju: Health Insurance Review and Assessment Service; 2018.
14 World Health Organization. Rational use of medicines [Internet]. Geneva: World Health Organization; 2007 [cited 2019 Dec 20]. Available from: http://who.int/medicines/areas/rational_use/en/.
15 World Health Organization. The pursuit of responsible use of medicines: sharing and learning from country experiences: technical report prepared for the Ministers Summit on the benefits of responsible use of medicines: setting policies for better and cost-effective health care. Geneva: World Health Organization; 2012.
16 Chapman S, Durieux P, Walley T. Good prescribing practice. In: Mossialos E, Mrazek MF, Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead: Open University Press; 2004. pp. 144-157.
17 Boston Consulting Group. Ensuring cost-effective access to innovative pharmaceuticals: do market interventions work? Boston (MA): The Boston Consulting Group; 1999.
18 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10(6):707-722. DOI: https://doi.org/10.1586/erp.10.72.   DOI
19 Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries: an overview. Generics Biosimilars Initiat J 2012;1(2):93-100. DOI: https://doi.org/10.5639/gabij.2012.0102.020.   DOI
20 Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev 2011;4(2):69-79. DOI: https://doi.org/10.5655/smr.v4i2.1004.   DOI